Skip to main content

Table 2 The research progress of stathmin and chemoresistance

From: Stathmin-dependent molecular targeting therapy for malignant tumor: the latest 5 years’ discoveries and developments

Publications

Cancer type

Cell lines

Tissues

Anticancer drugs

Notes

Sun [11]

Non-small cell lung cancer

No

Yes

Platinum; paclitaxel

High level of stathmin exhibits poor response to chemotherapy

Lin [78]

Yes

No

Taxol

Inhibition of stathmin expression increases sensitivity to taxol and promotes cellular apoptosis in NCI-H1299 cells

Lin [79]

Yes

No

Taxol

ERK-mediated stathmin is involved in taxol resistance of NCI-H1299 cells; blockage of ERK signal improves sensitivity of tumor cells to taxol

Han [80]

Yes

No

Paclitaxel

Inhibition of stathmin and Bcl-2 expression can sensitize lung cancer cells to paclitaxel

Feng [82]

Esophageal squamous carcinoma

Yes

No

Paclitaxel

Combined chemotherapeutic agent paclitaxel and stathmin siRNA can potentially enhance the therapeutic outcomes of paclitaxel in treating esophageal squamous cell cancer (ESCC)

Wang [16]

Yes

No

Paclitaxel

Silencing of stathmin gene can increase sensitivity of ESCC to paclitaxel and vincristine through G2/M phase block

Zhu [81]

Yes

No

Paclitaxel

Stathmin silencing by siRNA enhances sensitivity of esophageal cancer cells Eca-109 to paclitaxel and induces apoptosis

Balasubramani [83]

Breast cancer

Yes

No

Taxol

Stathmin overexpression protects the cells from taxol-induced abnormal mitoses, and thus induces taxol resistance

Miceli [48]

Yes

No

Taxol

Combination of anti-stathmin therapy and taxol has a more profound inhibition of tumorigenicity

Oda [84]

Yes

No

Zoledronic acid; gefitinib

Down-regulation of stathmin contributes to the effect that combined treatment of Zoledronic acid (Zol) and gefitinib inhibits both invasion and cell proliferation of the bone-seeking clone of breast cancer

Meng [61]

Gastric cancer

Yes

No

Docetaxel

Stathmin siRNA can improve the chemosensitivity of gastric cancer cells to docetaxel and promote apoptosis

Li [24]

Yes

No

Docetaxel

Stathmin mediates docetaxel resistance in transcription factor forkhead box protein M1 (FOXM1)FOXM1-silenced gastric cancer cells

Liu [25]

Yes

No

Docetaxel

Inhibition of stathmin enhances the inhibitory effects of docetaxel on the proliferation of gastric cancer cells

Werner [85]

Endometrial carcinoma

Yes

Yes

Paclitaxel

Knock-down of stathmin improves sensitivity to paclitaxel in endometrial carcinoma cells

Wosnitzer [35]

Bladder cancer

No

Yes

Taxane

Bladder cancer those who have tumors with low tau/stathmin protein expression show a better response to taxane

Mitra [86]

Retinoblastoma

Yes

Yes

Paclitaxel

Inhibition of stathmin enhances the cytotoxic effect of paclitaxel

Song [63]

Glioma

Yes

No

Temozolomide

Stathmin silencing inhibits invasion and enhances chemotherapy sensitivity of stem cells derived from glioma cells

Feng [87]

Osteosarcoma

Yes

No

Arsenic trioxide; doxorubicin

Down-regulation of stathmin significantly enhances reversion of ADM resistance in MG63/dox by As2O3

Wu [88]

Colorectal cancer

Yes

No

5-fluorouracil

Silencing of stathmin significantly improves chemoresponse to the classical colorectal cancer therapeutic agent, 5-FU

Watanabe [18]

Extrahepatic cholangiocarcinoma

Yes

Yes

Paclitaxel

Silencing of stathmin inhibits proliferation and increases sensitivity of extrahepatic cholangiocarcinoma cells to paclitaxel

  1. NCI-H1299 lung adenocarcinoma cell lines, ERK extracellular regulated protein kinases, Bcl-2 B-cell lymphoma-2, ESCC esophageal squamous cell cancer, shRNA short hairpin RNA, siRNA small interfering RNA, FOXM1 transcription factor forkhead box protein M1, ADM doxorubicin, As 2 O 3 arsenic trioxide, 5-FU 5-fluorouracil